Opyt primeneniya monoklonal'nykh antitel - blokatorov EGFR v lechenii metastaticheskogo kolorektal'nogo raka


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article analyzes the clinical data on the efficacy and safety of EGFR blockers in 87 patients in the 1-4 lines of drug therapy for metastatic colorectal cancer (mCRC) with wild-type RAS gene. In the 1st line therapy for metastatic process, EGFR blockers were for the first time assigned to 64.4% of patients. in the 2nd line therapy - to 14.9%, in the 3rd line - to 13.8% and in the 4th line - to 6.9% of patients. 14.9% of patients received EGFR blockers during the 2-3rd line therapy: they continued the anti-EGFR-therapy on the progression of the process (with the change of cytostatics). It is shown that the use of EGFR blockers for the treatment of mCRC as a 1st line therapy and in the later stages provides satisfactory overall survival and progression-free survival. Specific to EGFR blockers manifestations of dermal toxicity were expressed moderately and responded to medical correction. A significant increase in median overall survival from 13.4±4.3 to 25.8±4.9 months (p=0.04447) in those patients who continued treatment with EGFR blockers with change of line of chemotherapy with the progression of the process was observed. This approach can significantly expand the therapeutic options in mCRC with wild-type RAS gene and requires further study.

Full Text

Restricted Access

References

  1. Беляева А.В. Мутации в гене K-ras у больных колоректальным раком: эпидемиология и клиническое значение. Дисє. канд. мед. наук. СПб., 2012. 23 с.
  2. Jemal A. Global cancer statistics. CA Cancer J. Clin. 2011;2(61):69-90.
  3. Кит О.И. Проблема колоректального рака в начале XXI века: достижения и перспективы. Росс. журнал гастроэнтерол., гепатол., колопроктол. 2013;23(3):65-71.
  4. Allegra C.J., Jessup J.M., Somerfield M.R. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal первой, так и в последующих линиях терапии мКРР. Наиболее значимым среди результатов проведенного анализа является выявленное достоверное увеличение показателей ОВ у тех пациентов, которым была продолжена терапия блокаторами EGFR со сменой линии химиотерапии при прогрессировании процесса. Подобный подход существенно расширяет терапевтические возможности при мКРР без дополнительных лекарственных агентов и увеличения токсичности проводимого лечения. growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009;27(12):2091-96.
  5. Amado R., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman DJ., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:1626-34.
  6. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A.,Neyns B.,Canon J.L., VanLaethemJ.L., Maurel J., Richardson G., Wolf M., Amado R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007;25:1658-64
  7. Владимирова Л.Ю., Геворкян Ю.А., Абрамова Н.А. и др. Оценка эффективности и токсичности моноклонального антитела к EGFR панитумумаба при колоректальном раке. VII съезд онкологов и радиологов стран СНГ. 2012.
  8. Vladimirova L.Y., Kit O.I., Nikipelova E.A. et al. Resilts of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer.J Clin Oncol. 49th Annual Meeting of ASCO. 2013;15(31 [suppl.]):800S-e19047.
  9. Nordlinger B, van Cutsem E., Gruenberger T., Glimelius B, Poston G., Rougier P., Sobrero A., Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 2009;20(6):985-92.
  10. Van Cutsem E., Humblet Y., et al. Cetuximab dose-escalation study in patients with nCRC with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): preliminary PK and efficacy date of a randomized study. Proc. of ASCO 2007;Abstract 237.
  11. Stintzing S., Jung A., Rossius L. et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.2013 European Cancer Congress. Abstract 17.
  12. Cascinu S., Rosati G., Nasti G. et al. A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. Eur. J. of Cancer. 2015;51(suppl. S3):S329. [Abstr. Book ECCO-ESMO 2015].
  13. Abramova N., Vladimirova L., Kit O. Monoclonal antibodies against EGFR-receptors in metastatic colorectal cancer (mCRC) treatment: comparative tolerability and efficacy of Panitumumab (P) and Cetuximab (C). 2014 ASCO Annual Meeting. Abstr. 1070.
  14. Price T., et al. ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). The European Cancer Congress 2013, Sep 29. Abstr. 18.
  15. Douillard J., Siena S., Cassidy J. et al. Randomized Phase 3 Study of Panitumumab with FOLFOX4 vs FOLFOX4 Alone as First-line Treatment in Patients with Metastatic Colorectal Cancer: the PRIME Trial. Eur. J. Cancer. 2009;7(3 suppl):10LBA.
  16. Humblet Y., Peeters M., Siena S. et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). American Society of Clinical Oncology, Chicago, 2007; Abstr. 4038.
  17. Варламова С.Е., Антимоник Н.Ю., Козлова Н.М., Макеев Ю.М., Бердов Б.А., Болотина Л.В., Владимирова Л.Ю., Феоктистова П.С., Орлова Е.В., Птушкин В.В. Отечественный опыт профилактики и лечения проявлений кожной токсичности у пациентов мКРР, получающих ингибиторы EGFR, на примере панитумумаба. Проект RUSSCO по разработке рекомендаций по коррекции дерматологических реакций у пациентов, получающих терапию ингибиторами EGFR. Злокачественные опухоли. 2013; 3(7):42-51.
  18. Ciardiello F., Normanno N., Martinelli E, Troanil T., Cardonel C., Nappil A. et al. Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab. Ann. Oncol. 2015;26(suppl 4):iv120-iv121.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies